Dyne Therapeutics (DYN) News Today

Seven Eight Capital LP purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 18,171 shares of the company's stock, valued at approximately $

Dyne Therapeutics (NASDAQ:DYN) Reaches New 12-Month High at $44.38

Swiss National Bank increased its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 41.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 85,200 shares of the company's stock after purchasin

Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down to $44.15

Oppenheimer & Co. Inc. bought a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 28,529 shares of the company's stock, valued at approximately $810,000. Other h

Dyne Therapeutics (NASDAQ:DYN) Sets New 12-Month High at $44.30

Concurrent Investment Advisors LLC acquired a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 20,200 shares of the comp

Lisanti Capital Growth LLC acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 86,610 shares of the company's stock, valued at approximately $2,459,

Atlas Venture Life Science Advisors LLC cut its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 18.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,020,136 shares of the company

Jennison Associates LLC raised its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 495.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,207,551 shares of the company's

Dyne Therapeutics (NASDAQ:DYN) Trading Up 3.5% After Analyst Upgrade

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) has been assigned a consensus rating of "Buy" from the nine brokerages that are presently covering the company, Marketbeat reports. Eight analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to

Wasatch Advisors LP decreased its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 75.2% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 417,794 shares of the company's stock after sellin

Dyne Therapeutics (NASDAQ:DYN) Stock Price Up 3.9%

Vida Ventures Advisors LLC cut its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 80.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 407,499 shares of the company's stock after sel

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) COO Susanna Gatti High sold 10,163 shares of Dyne Therapeutics stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $35.33, for a total transaction of $359,058.79. Following the transaction, the chief operating officer now directly owns 148,792 shares of the company's stock, valued at $5,256,821.36. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Dyne Therapeutics (NASDAQ:DYN) Hits New 12-Month High at $36.23

Dyne Therapeutics (NASDAQ:DYN) Trading 5.2% Higher

Octagon Capital Advisors LP boosted its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 14.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 792,945 shares of the company's stock after acqui

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) COO Susanna Gatti High sold 40,000 shares of the business's stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $33.36, for a total transaction of $1,334,400.00. Following the completion of the sale, the chief operating officer now directly owns 148,792 shares of the company's stock, valued at $4,963,701.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Frazier Life Sciences Management L.P. bought a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 1,184,840 shares of the company's stock, valued at approximately $15,

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) has been given a consensus recommendation of "Buy" by the nine research firms that are covering the company, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommen

Dyne Therapeutics (NASDAQ:DYN) Trading 8.8% Higher

Commodore Capital LP purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 900,000 shares of the company'

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) SVP Richard William Scalzo sold 1,590 shares of the company's stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $30.23, for a total transaction of $48,065.70. Following the sale, the senior vice president now directly owns 115,105 shares in the company, valued at approximately $3,479,624.15. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Rafferty Asset Management LLC increased its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 17.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 164,041 shares of the company's stock after purchasing an additional 24,632 shares during t

Armistice Capital LLC lowered its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 31.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 824,000 shares of the

Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Analysts at Chardan Capital increased their FY2024 earnings per share estimates for Dyne Therapeutics in a research report issued on Tuesday, May 28th. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings per share

Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down to $32.63

Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - HC Wainwright increased their FY2025 earnings per share (EPS) estimates for Dyne Therapeutics in a research report issued to clients and investors on Monday, May 20th. HC Wainwright analyst A. Fein now expects that the company will earn ($1.41)

Dyne Therapeutics (NASDAQ:DYN) Reaches New 12-Month High Following Analyst Upgrade

Chardan Capital upped their target price on shares of Dyne Therapeutics from $31.00 to $42.00 and gave the company a "buy" rating in a report on Tuesday.